REGULATION BRIEFING

EU GMP Annex 11 and Annex 22: What the Digital Rewrite Means for Contract Manufacturing

Europe is rewriting the GMP rules for computerized systems and documentation for the first time since 2011, and adding the first GMP annex on artificial intelligence. The drafts of Annex 11, Chapter 4 and the new Annex 22 were written with PIC/S, so they will reach inspectorates well beyond the EU. Final texts are due to go to the European Commission by the end of 2026.

EU GMP digital revisions: latest updates

  • Nov 2026: EudraLex Volume 4 still lists the 2011 versions of Annex 11 and Chapter 4, and Annex 22 remains a draft.
  • Oct 2026: EMA published the report of its expert workshop on Annex 22. It records that the drafting group has discussed widening the scope to cover generative and probabilistic AI.
  • Jun 30 to Jul 1, 2026: EMA held a two-day workshop to gather input on guardrails that could allow a risk-based use of generative AI in manufacturing.
  • Mar 23, 2026: EMA’s 2026–2028 inspectors’ work plan set Q4 2026 as the target to hand all three final texts to the Commission, after an earlier Q1 2026 target slipped.

EU GMP digital revisions at a glance

RegionEuropean Union, plus PIC/S member inspectorates that adopt the texts
InstrumentsEudraLex Volume 4: revised Chapter 4 (documentation), revised Annex 11 (computerized systems), new Annex 22 (artificial intelligence)
Drafted byEMA GMP/GDP Inspectors Working Group with PIC/S
ConsultationJuly 7 to October 7, 2025, with roughly 1,300 comments
Legal statusProposed or draft; 2011 texts still apply
Key dateFinal texts to the Commission targeted for Q4 2026; transition period not yet announced
Who it bindsEvery manufacturer and importer under EU GMP, including CDMOs, CROs with GMP labs and their software suppliers
Most exposedCDMOs running multi-client MES, LIMS and QMS platforms, and sites testing AI in quality operations
Official sourceEuropean Commission
PharmaSource Score224 (rank 10)
Impact 4, Reach 7, Likelihood 8
Download the PharmaSource Regulatory Radar

What the EU GMP digital revisions are

The current Annex 11 dates from 2011, before cloud software, remote access and machine learning reached the plant floor. The rewrite turns a short, interpretive annex into a detailed rulebook. The draft Annex 11 grows from 5 to 19 pages, and Chapter 4 from 9 to 17.

The package works through six levers:

  • Audit trails in daily work: Systems must record all user activity, protect the trail from alteration, and have it reviewed as part of routine work as well as at periodic checks.
  • Identity and access: Individual accounts, strong access control and second-factor authentication at the point of electronic signature.
  • Cybersecurity as GMP: Penetration testing, timely patching and incident response become inspection topics.
  • Supplier and cloud oversight: Written agreements with software and hosting providers must cover data ownership, access and security, backed by ongoing monitoring and audits.
  • Data governance: Chapter 4 writes ALCOA++ into GMP, requires a data governance system inside the quality system, and covers hybrid paper-electronic records and electronic signatures.
  • AI in critical uses: Annex 22 allows only static, deterministic models in applications that affect patient safety, product quality or data integrity. Models need a defined intended use, independent test data, explainable outputs and a route to a qualified human.

The draft Annex 22 states that generative AI and large language models “should not be used in critical GMP applications.” They remain allowed for non-critical work, such as drafting, as long as a qualified person checks the output.

Where the EU GMP digital revisions stand

  • November 2022: EMA and PIC/S publish a concept paper on revising Annex 11.
  • July 7, 2025: Drafts of all three texts open for a joint EU and PIC/S consultation.
  • October 7, 2025: The consultation closes with about 1,300 comments.
  • January 14, 2026: EMA and FDA publish ten guiding principles for AI across the medicine lifecycle, including manufacturing.
  • Mid-2026: The target for final texts moves to Q4 2026, and EMA reopens the question of generative AI.

Annex 22 is the open question. Industry wants room to use large language models in quality work, and EMA’s workshop suggests regulators are weighing conditions for that use. Annex 11 and Chapter 4 look more settled, but the length of the transition period, which decides how fast sites must comply, has not been announced.

What the EU GMP digital revisions mean for manufacturing and outsourcing

These rules change no supply routes, but they reach every validated system on every EU GMP site. CDMOs carry the heaviest load because they run shared platforms that hold many clients’ data.

PharmaSource research shows how far many CDMOs have to go. In the AI + Digital Maturity in Contract Manufacturing 2026 report with MasterControl, 40% of the 93 respondents run AI beyond the pilot stage, up from 23% in 2025, and 62% expect significant value from AI within two years. The foundations lag behind: only 12% run a manufacturing execution system, and only 25% have integrated electronic batch records, so many AI pilots still run on paper and spreadsheets. Annex 22’s demands for traceable training data and documented intended use will be hardest to meet on those foundations. The exposure differs by company:

  • CDMOs: Multi-client MES, LIMS and QMS platforms need gap assessments, revalidation, tighter access control and audit-trail review built into daily work. Sponsors will ask for evidence during audits.
  • Sponsors: The supplier-oversight rules make sponsors check how their CDMOs manage cloud software and data access, and quality agreements will need new clauses on data ownership and system access. Live batch visibility is already sponsors’ top request of CDMOs, at 35% in the PharmaSource survey.
  • Software and cloud vendors: Vendors face audits and contract terms covering security, change notification and data return.
  • Sites outside the EU: Plants supplying the EU face these rules at EU inspections, and PIC/S co-authorship means more than 50 authorities could adopt them.
  • Early AI adopters: Sites using machine learning for visual inspection, process monitoring or batch review must document intended use, test data and human oversight, or hold back until the final text lands.

Aizon strategic advisor David O’Gara told PharmaSource that “effective sharing requires a foundational trust between sponsors and CDMOs,” and advised introducing digital tools incrementally. For outsourcing leaders, the practical step is to ask each EU CDMO for a gap assessment against the drafts, a timeline for revalidation, and a list of any AI tools touching GMP data.

Why supporters back the EU GMP digital revisions

“A very good starting point to amend the missing aspects of the previous regulation.”

ECA Academy, on the draft Annex 11, via GMP-Compliance.org
  • Overdue update: The 2011 annex predates cloud hosting, remote access and AI, and inspectors have been applying it by interpretation.
  • Cyber risk: The ECA notes that security threats increasingly affect the regulated industry, and the draft makes security a GMP duty for the first time.
  • Clarity for AI: A dedicated annex tells sites what evidence inspectors expect before AI touches a release decision.
  • Harmonization: Joint drafting with PIC/S means one standard across most major inspectorates.

Criticisms of the EU GMP digital revisions

“Making HOW as requirement would have a negative impact.”

ISPE, in its consultation comments on the draft Annex 11
  • Too prescriptive: ISPE argues the draft dictates how to comply, where industry guidance already covers that.
  • Cost of revalidation: Sites face the expense of upgrading or replacing systems that met the 2011 rules.
  • AI rules built for yesterday’s models: Consultant Brian Drapeau argues in PharmTech that the draft’s test, explanation and frozen-model requirements are hard or impossible to meet for large language models.
  • Inconsistencies: ISPE flagged gaps between the texts, such as Chapter 4 defining ALCOA++ while Annex 11 refers to ALCOA+.
  • Uncertain timing: The final-text target has already slipped once, and no transition period has been set.

What’s next for the EU GMP digital revisions

  • Q4 2026: EMA’s inspectors aim to send final texts to the Commission.
  • Publication: The Commission publishes the texts in EudraLex Volume 4 with an effective date. Watch whether Annex 22 now admits generative AI under conditions.
  • Transition: The transition period sets how long sites have to comply. Annex 1’s revision gave one year, which Elisabeth Stampa of Medicines for Europe told CDMO Live was “like a big shock.”
  • PIC/S adoption: Member authorities then adopt the texts into their own GMP guides.
  • December 3, 2026: PharmaSource and MasterControl discuss the digital maturity findings in a live webinar; one registration covers the full report and the session.
  • Our score: Impact 4, Reach 7, Likelihood 8, giving 224 and rank 10. The rules raise compliance cost without changing where products are made, so Impact stays modest; Likelihood rises once the texts are published.

Related articles

Tracking global policies and their impact on biopharma manufacturing
REGULATORY RADAR
Full tracker of regulation changing biopharma manufacturing and supply.
Free to access and updated daily.